Population Pharmacokinetics of an Angiotensin II Receptor Antagonist, Telmisartan, in Healthy Volunteers and Hypertensive Patients

Drug Metabolism And Pharmacokinetics

Volumn 18, Issue 3, 2003, Pages 203-211

  Tatami, Shinji ^a   Sarashina, Akiko ^a   Yamamura, Norio ^a   Igarashi, Takashi ^a   Tanigawara, Yusuke ^b  

^a NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

covariate; model validation; modeling; NONMEM; population pharmacokinetics; telmisartan

Indexed keywords

EID: 85009545147     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.18.203     Document Type: Article

References (20)

1. Wienen, W., Hauel, N., Van Meel, J. C., Narr, B., Ries, U. and Entzeroth, M.: Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br. J. Pharmacol., 110: 245-252 (1993).
2. Wienen, W., Entzeroth, M., Meel, J. C. A., Stangier, J., Busch, U., Ebner, T., Schmid, J., Lehmann, H., Matzek, K., Kempthorne-Rawson, J., Gladigau, V. and Hauel, N. H.: A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc Drug Rev., 18: 127-156 (2000).
3. Neutel, J. M. and Smith, D. H. G.: Dose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv. Ther., 15: 206-217 (1998).
4. Smith, D. H. G., Matzek, K. M. and Kempthorne-Rawson, J.: Dose response and safety of telmisartan in patients with mild to moderate hypertension. J. Clin. Pharmacol., 40: 1380-1390 (2000).
5. Stangier, J., Su, C. A. and Roth, W.: Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J. Int. Med. Res., 28: 149-167. (2000).
6. Stangier, J., Schmid, J., Turck, D., Switek, H., Verhagen, A., Peeters, P. A., van Marle, S. P., Tamminga, W. J., Sollie, F. A. and Jonkman, J. H.: Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers. J. Clin. Pharmacol., 40: 1312-1322 (2000).
7. Stangier, J., Su, C. A., Schondorfer, G. and Roth, W.: Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. J. Clin. Pharmacol., 40: 1355-1364 (2000).
8. Williams, P. J. and Ette, E. I.: The role of population pharmacokinetics in drug development in light of the Food and Drug Administration's 'Guidance for industry: population pharmacokinetics'. Clin. Pharmacokinet., 39: 385-395. (2000).
9. FDA: Guidance for industry: population pharmacokinetics. (1999).
10. Ogihara, T., Minami, F., Kainuma, H., Asai, Y., Okada, Y., Fukuyo, K., Nakamura, Y., Osaka, A. and Tatami, S.: Pharmacokinetic evaluation of an angiotensin II AT1 receptor antagonist, BIBR277 (Telmisartan) in hypertensive patients. Jpn. Pharmacol. Ther. (in Japanese), 30: S271-S283 (2002).
11. Ogihara, T., Sakai, R., Fujita, Y., Shinko, S., Azekura, H., Obayashi, T., Tsuruta, Y. and Tatami, S.: Pharmacokinetics of BIBR277 (Telmisartan) in hypertensive patients with renal insufficiency. Jpn. Pharmacol. Ther. (in Japanese), 30: S183-S199 (2002).
12. Ogihara, T., Takaori, A., Taki, C., Asai, Y., Yajima, K., Fukuda, H. and Tatami, S.: Pharmacokinetics of BIBR277 (Telmisartan) in patients with essential hypertension. Jpn. Pharmacol. Ther. (in Japanese), 30: S235-251 (2002).
13. Irie, S., Ogihara, T. and Tatami, S.: Influence of food on the bioavailability of single oral dose of BIBR277 (Telmisartan). Jpn. Pharmacol. Ther. (in Japanese), 30: S201-S208 (2002).
14. Boeckmann, A. J., Sheiner, L. B. and Beal, S. L.: NONMEM users guide. NONMEM Project Group, University of California at San Francisco. (1998).
15. Ette, E. I.: Stability and performance of a population pharmacokinetic model. J. Clin. Pharmacol., 37: 486-495. (1997).
16. Israili, Z. H.: Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J. Hum. Hypertens., 14 Suppl 1: S73-S86 (2000).
17. Sharpe, M., Jarvis, B. and Goa, K. L.: Telmisartan: a review of its use in hypertension. Drugs, 61: 1501-1529. (2001).
18. Schmid, J., Beschke, K., Prox, A., Ebner, T., Busch, U., Koebe, H. G., Pahernik, S. and Schildberg, F. W.: In vivo and in vitro biotransformation of telmisartan, human hepatocyte cultures as an aid in human metabolic studies. Exp. Toxicol. Pathol., 48: 387 (1996).
19. Ebner, T. and Roth, W.: In vitro glucuronidation of telmisartan, a novel angiotensin II receptor antagonist. J. Hum. Hypertens., 13 Suppl 3: S12 (1999).
20. Mackenzie, P. I., Miners, J. O. and McKinnon, R. A.: Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance. Clin. Chem. Lab. Med., 38: 889-892. (2000).